MYC and B-cell non-Hodgkin lymphoma: Four types of malignant lymphoma, including diffuse large B‐cell lymphoma, follicular‐lymphoma, Hodgkin's‐lymphoma, and mantle cell lymphoma, constituted more than half of all new lymphoma cases occurring worldwide.13 BL, a highly aggressive B‐cell NHL, is characterized by the activation of the most frequent amplified oncogene in human cancers (MYC) oncogene along with other genetic and epigenetic factors.14 Efforts have been made to improve the current methods of therapy for this rapidly growing type of neoplasm and for these therapies to have minimal treatment‐associated toxicities.15